title: Analysis of longterm survivors with expandable metallic stent inserted for malignant biliary stenosis.
abstract: OBJECTIVE
  Some patients with unresectable malignant biliary stenosis can survive for more than 1 year after the insertion of self-expandable metallic stents (SEMS). The aim of this study was to analyze the background of the longterm survivors.
  
  
  METHODS
  In our study, 111 patients with inserted SEMS were divided into two groups: patients who died within 1 year and patients still alive for more than 1 year. The parameters analyzed were survival rate, survival period, patent period of the inserted SEMS, adjuvant therapy, and complications.
  
  
  RESULTS
  The number of those who survived for more than 1 year totaled 24 (21.6%). Their diagnoses were bile duct carcinoma (15/31; 48.4%) and pancreas carcinoma (9/28; 32.9%). There were no survivors with other diseases. The survival period and stent-patent period of the patients with bile duct carcinoma (429.2 days and 589.7 days, respectively) and pancreas carcinoma (270.1 days and 336.4 days, respectively) were significantly longer than those of the patients with other diseases. The specific complication of the longterm survivors was duodenal obstruction.
  
  
  CONCLUSIONS
  Many patients with bile duct carcinoma and pancreas carcinoma survived for more than 1 year and adjuvant therapy should be performed to improve the survival of those patients.
authors.affiliation: Department of Internal Medicine, Hiroshima City Hospital, 7-13 Motomachi, Naka-ku, Hiroshima 730-8515, Japan.
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Kawamoto
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Ishii
authors.forename: Masahiro
authors.initials: M
authors.lastname: Nakagawa
authors.forename: Toru
authors.initials: T
authors.lastname: Sugihara
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001650:Bile Duct Neoplasms / Q000401:mortality / Q000601:surgery*; D001652:Bile Ducts / Q000473:pathology*; D017024:Chemotherapy, Adjuvant; D003251:Constriction, Pathologic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010166:Palliative Care; D010190:Pancreatic Neoplasms / Q000401:mortality / Q000601:surgery*; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D015607:Stents; D016019:Survival Analysis; D017741:Survivors